Lifecore Biomedical EBITDA vs. Price To Book
| LFCR Stock | 7.41 0.09 1.20% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 35.6 M | Current Value 37.4 M | Quarterly Volatility 26.3 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.17 | 0.3263 |
|
| |||||
| Operating Profit Margin | 0.0069 | 0.0728 |
|
| |||||
| Pretax Profit Margin | 0.0011 | 0.0742 |
|
|
For Lifecore Biomedical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lifecore Biomedical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lifecore Biomedical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lifecore Biomedical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lifecore Biomedical over time as well as its relative position and ranking within its peers.
Lifecore |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lifecore Biomedical. If investors know Lifecore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lifecore Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.13 | Revenue Per Share 4.199 | Quarterly Revenue Growth 0.007 | Return On Assets (0.02) | Return On Equity 0.1729 |
The market value of Lifecore Biomedical is measured differently than its book value, which is the value of Lifecore that is recorded on the company's balance sheet. Investors also form their own opinion of Lifecore Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Lifecore Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lifecore Biomedical's market value can be influenced by many factors that don't directly affect Lifecore Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lifecore Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lifecore Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lifecore Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lifecore Biomedical Price To Book vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lifecore Biomedical's current stock value. Our valuation model uses many indicators to compare Lifecore Biomedical value to that of its competitors to determine the firm's financial worth. Lifecore Biomedical is rated second overall in ebitda category among its peers. It is currently regarded as number one stock in price to book category among its peers . The ratio of EBITDA to Price To Book for Lifecore Biomedical is about 2,319,978 . At this time, Lifecore Biomedical's EBITDA is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lifecore Biomedical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Lifecore Price To Book vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Lifecore Biomedical |
| = | 35.6 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Lifecore Biomedical |
| = | 15.35 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Lifecore Price To Book Comparison
Lifecore Biomedical is currently under evaluation in price to book category among its peers.
Lifecore Biomedical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lifecore Biomedical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lifecore Biomedical will eventually generate negative long term returns. The profitability progress is the general direction of Lifecore Biomedical's change in net profit over the period of time. It can combine multiple indicators of Lifecore Biomedical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -39.2 M | -37.3 M | |
| Operating Income | 9.3 M | 5.7 M | |
| Income Before Tax | 9.5 M | 10 M | |
| Total Other Income Expense Net | 183 K | 192.2 K | |
| Net Income | 9.3 M | 9.8 M | |
| Income Tax Expense | 183 K | 173.8 K | |
| Net Interest Income | -18.1 M | -19 M | |
| Interest Income | 61.2 K | 71.2 K | |
| Net Income From Continuing Ops | 9.3 M | 9.8 M | |
| Net Loss | -92 M | -87.4 M | |
| Change To Netincome | 37 M | 31.8 M | |
| Net Loss | 0.39 | (0.08) | |
| Income Quality | (0.02) | 0.07 | |
| Net Loss | 1.26 | (7.40) |
Lifecore Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lifecore Biomedical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lifecore Biomedical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lifecore Biomedical's important profitability drivers and their relationship over time.
Use Lifecore Biomedical in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.Lifecore Biomedical Pair Trading
Lifecore Biomedical Pair Trading Analysis
The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.
The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lifecore Biomedical position
In addition to having Lifecore Biomedical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alcohol Thematic Idea Now
Alcohol
Companies involved in production and distribution of wines and alcoholic beverages. The Alcohol theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alcohol Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.